Incyte Corp (INCY) 117.53 $INCY
Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase 3 Data
PR Newswire - Tue Oct 27, 12:00PM CDT
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) will host a webcast on November 11 to discuss detailed data from the final two of four pivotal Phase 3 studies of baricitinib in rheumatoid arthritis. Data from these two trials, RA-BEGIN and RA-BEAM, will be presented on November 8 and November 10, respectively, during the 2015 ACR/ARHP Annual Meeting in San Francisco, California.
INCY: 117.53 (+0.50), LLY: 81.57 (-0.43)
Incyte Rises 2.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Oct 26, 4:50PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $107.11 to a high of $114.00. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $113.87 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 117.53 (+0.50)
Look for Shares of Incyte to Potentially Pullback after Yesterday's 2.06% Rise
Comtex SmarTrend(R) - Mon Oct 26, 4:50PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $107.11 to a high of $114.00. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $113.87 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 117.53 (+0.50)
Northwest Bio Bothers British Bestie for Bounteous Bucks
at The Street - Thu Oct 22, 11:18AM CDT
British investor Woodford appears to be the only institutional investor supporting Northwest Bio and its claims of "encouraging interim clinical data" from its DCVax-L and DCVax-Direct cancer immunotherapy clinical programs.
NWBO: 4.88 (+0.01), KITE: 68.05 (-0.72), AZN: 31.89 (-0.35), MRK: 54.66 (-0.21), INCY: 117.53 (+0.50), JUNO: 51.76 (+0.37), BMY: 65.95 (-1.36), NVS: 90.43 (-0.53), FPRX: 32.15 (+0.27)
Polycythemia Vera Pipeline Review, H2 2015 - 10 Companies & 12 Drug Profiles
M2 - Thu Oct 22, 8:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wswf9z/polycythemia_vera) has announced the addition of the "Polycythemia Vera - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Galena Biopharma, Inc. - Gilead Sciences, Inc. - Incyte Corporation - Italfarmaco S.p.A. - Karus Therapeutics Limited - miRagen Therapeutics, Inc. - Novartis AG - Onconova Therapeutics, Inc. - PharmaEssentia Corporation Drug Profiles - anagrelide hydrochloride CR - dasatinib - erismodegib - givinostat - idelalisib - KA-1463 - M-012 - MGN-4893 - momelotinib dihydrochloride - rigosertib sodium - ropeginterferon ALFA-2B - ruxolitinib phosphate For more information visit http://www.researchandmarkets.com/research/ws...hemia_vera
GILD: 108.13 (-1.08), INCY: 117.53 (+0.50), ONTX: 1.36 (-0.04), GALE: 1.68 (-0.05), BMY: 65.95 (-1.36), NVS: 90.43 (-0.53)
5 Immunotherapy Stocks to Watch for Treating Cancer
Arpita Dutt - Zacks Investment Research - Fri Oct 16, 2:23PM CDT
Given the growing interest in immuno-oncology treatments, here's a peek at some companies that are looking to change the way to treat cancer.
KITE: 68.05 (-0.72), MRK: 54.66 (-0.21), INCY: 117.53 (+0.50), AZN: 31.89 (-0.35), CNCR: 27.65 (-0.24), AMGN: 158.18 (-2.40), JUNO: 51.76 (+0.37)
Incyte Rises 6.24% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Oct 15, 4:17PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $104.57 to a high of $112.67. Yesterday, the shares gained 6.2%, which took the trading range above the 3-day high of $108.99 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 117.53 (+0.50)
After Yesterday's Rally of 6.24% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Oct 15, 4:16PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $104.57 to a high of $112.67. Yesterday, the shares gained 6.2%, which took the trading range above the 3-day high of $108.99 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 117.53 (+0.50)
Lilly-Incyte drug beats Humira
at Investor's Business Daily - Wed Oct 14, 5:35PM CDT
Rheumatoid arthritis drug baricitinib, created by Eli Lilly (LLY) and its partner Incyte (INCY), outperformed AbbVie's (ABBV) market-leading Humira in a clinical trial, the partners said. The study's primary endpoint was just to do better than a...
INCY: 117.53 (+0.50), ABBV: 59.55 (+5.45), LLY: 81.57 (-0.43)
Incyte & Merck Expand Melanoma Treatment Collaboration
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 2:50PM CDT
Incyte (INCY) and Merck (MRK) have expanded their collaboration agreement by including a phase III study on epacadostat in combination with Keytruda.
MRK: 54.66 (-0.21), INCY: 117.53 (+0.50), ANIK: 38.52 (-0.55), NVET: 4.35 (unch)
Eli Lilly, Incyte's Baricitinib Scores in Phase III Study
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 2:30PM CDT
Eli Lilly (LLY) and Incyte's baricitinib tops phase III rheumatoid arthritis study; strikes a T-cell-based immuno-oncology research collaboration ImaginAb Inc.
MRK: 54.66 (-0.21), INCY: 117.53 (+0.50), JUNO: 51.76 (+0.37), LLY: 81.57 (-0.43)
Lilly-Incyte Drug Beats Humira In Arthritis Trial
at Investor's Business Daily - Wed Oct 14, 10:12AM CDT
Big pharma Eli Lilly (LLY) and its biotech partner Incyte (INCY) said Wednesday that their rheumatoid-arthritis drug outperformed AbbVie's (ABBV) market-leading Humira in a clinical trial, sending both stocks higher. The study's primary endpoint for...
PFE: 33.82 (-0.95), INCY: 117.53 (+0.50), ABBV: 59.55 (+5.45), LLY: 81.57 (-0.43)
Why Incyte Corporation (INCY) Isn't Done Growing Earnings Yet
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 7:48AM CDT
Incyte Corporation (INCY) has double digit earnings growth prospect as it sees rising earnings estimates, coupled with a solid Zacks Rank.
INCY: 117.53 (+0.50)
Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study
PR Newswire - Wed Oct 14, 5:45AM CDT
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis.
INCY: 117.53 (+0.50), LLY: 81.57 (-0.43)
Incyte to Report Third Quarter Financial Results
Business Wire - Tue Oct 13, 7:00AM CDT
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its third quarter 2015 financial results conference call and webcast for 10:00 a.m. ET on Tuesday, November 3, 2015.
INCY: 117.53 (+0.50)
Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda(R) (pembrolizumab) as First-line Treatment for Advanced Melanoma
Business Wire - Tue Oct 13, 6:30AM CDT
Incyte Corporation (Nasdaq: INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the expansion of the companies' ongoing clinical collaboration to include a Phase 3 study evaluating the combination of epacadostat, Incyte's investigational selective IDO1 inhibitor, with Keytruda(R) (pembrolizumab), Merck's anti-PD-1 therapy, as first-line treatment for patients with advanced or metastatic melanoma. The Phase 3 study, which is expected to begin in the first half of 2016, will be co-funded by Incyte and Merck.
MRK: 54.66 (-0.21), INCY: 117.53 (+0.50)
Why Incyte Corporation (INCY) Could Shock the Market Soon
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 7:40AM CDT
Incyte has seen a negative price movement but large positive earnings estimate revisions make it an unappreciated stock that might have potential for gains
INCY: 117.53 (+0.50)
3 Reasons Why Incyte Corporation (INCY) is a Great Momentum Stock
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 7:30AM CDT
Incyte Corporation (INCY) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
INCY: 117.53 (+0.50)
3 Large-Cap Biotech Stocks Whose Valuations Should Make You Skeptical
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 07, 7:03AM CDT
Source: Federal Reserve Bank of New York. With the exception of the last couple of weeks, the biotech sector has been a vast outperformer since the Great Recession. The broad-based S&P 500 has pretty much tripled since hitting its lows in...
BIIB: 290.51 (-3.21), VRTX: 124.74 (-1.43), XBI: 66.63 (-0.68), INCY: 117.53 (+0.50)
Global Indolent Lymphoma Pipeline Review, H2 2015 - 17 Companies & 25 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q2nmbb/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Altor BioScience Corporation - Astellas Pharma Inc. - Bayer AG - Biothera, Inc. - Boehringer Ingelheim GmbH - Celgene Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Juno Therapeutics Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - MorphoSys AG Drug Profiles - acalisib - ALT-803 - bendamustine hydrochloride - BI-836826 - CC-122 - copanlisib hydrochloride - DI-B4 - duvelisib - entospletinib - ibrutinib - idelalisib - Imprime PGG - INCB-39110 - INCB-40093 - INCB-50465 - JCAR-015 - KTE-C19 - lenalidomide - MEDI-0680 - MEDI-551 - MEDI-551 MEDI-0680 - MOR-208 - obinutuzumab - venetoclax - vorinostat For more information visit http://www.researchandmarkets.com/research/q2...t_lymphoma
KITE: 68.05 (-0.72), GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), INCY: 117.53 (+0.50), JUNO: 51.76 (+0.37), INFI: 10.35 (+0.08), ABBV: 59.55 (+5.45), CELGZ: 1.65 (+0.17)
Lilly and Incyte Announce Webcast to Discuss Baricitinib Phase 3 Data
PR Newswire - Tue Oct 27, 12:00PM CDT
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (Nasdaq: INCY) will host a webcast on November 11 to discuss detailed data from the final two of four pivotal Phase 3 studies of baricitinib in rheumatoid arthritis. Data from these two trials, RA-BEGIN and RA-BEAM, will be presented on November 8 and November 10, respectively, during the 2015 ACR/ARHP Annual Meeting in San Francisco, California.
INCY: 117.53 (+0.50), LLY: 81.57 (-0.43)
Incyte Rises 2.06% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Mon Oct 26, 4:50PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $107.11 to a high of $114.00. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $113.87 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 117.53 (+0.50)
Look for Shares of Incyte to Potentially Pullback after Yesterday's 2.06% Rise
Comtex SmarTrend(R) - Mon Oct 26, 4:50PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $107.11 to a high of $114.00. Yesterday, the shares gained 2.1%, which took the trading range above the 3-day high of $113.87 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 117.53 (+0.50)
Northwest Bio Bothers British Bestie for Bounteous Bucks
at The Street - Thu Oct 22, 11:18AM CDT
British investor Woodford appears to be the only institutional investor supporting Northwest Bio and its claims of "encouraging interim clinical data" from its DCVax-L and DCVax-Direct cancer immunotherapy clinical programs.
NWBO: 4.88 (+0.01), KITE: 68.05 (-0.72), AZN: 31.89 (-0.35), MRK: 54.66 (-0.21), INCY: 117.53 (+0.50), JUNO: 51.76 (+0.37), BMY: 65.95 (-1.36), NVS: 90.43 (-0.53), FPRX: 32.15 (+0.27)
Polycythemia Vera Pipeline Review, H2 2015 - 10 Companies & 12 Drug Profiles
M2 - Thu Oct 22, 8:28AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wswf9z/polycythemia_vera) has announced the addition of the "Polycythemia Vera - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Polycythemia Vera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Polycythemia Vera and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Galena Biopharma, Inc. - Gilead Sciences, Inc. - Incyte Corporation - Italfarmaco S.p.A. - Karus Therapeutics Limited - miRagen Therapeutics, Inc. - Novartis AG - Onconova Therapeutics, Inc. - PharmaEssentia Corporation Drug Profiles - anagrelide hydrochloride CR - dasatinib - erismodegib - givinostat - idelalisib - KA-1463 - M-012 - MGN-4893 - momelotinib dihydrochloride - rigosertib sodium - ropeginterferon ALFA-2B - ruxolitinib phosphate For more information visit http://www.researchandmarkets.com/research/ws...hemia_vera
GILD: 108.13 (-1.08), INCY: 117.53 (+0.50), ONTX: 1.36 (-0.04), GALE: 1.68 (-0.05), BMY: 65.95 (-1.36), NVS: 90.43 (-0.53)
5 Immunotherapy Stocks to Watch for Treating Cancer
Arpita Dutt - Zacks Investment Research - Fri Oct 16, 2:23PM CDT
Given the growing interest in immuno-oncology treatments, here's a peek at some companies that are looking to change the way to treat cancer.
KITE: 68.05 (-0.72), MRK: 54.66 (-0.21), INCY: 117.53 (+0.50), AZN: 31.89 (-0.35), CNCR: 27.65 (-0.24), AMGN: 158.18 (-2.40), JUNO: 51.76 (+0.37)
Incyte Rises 6.24% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Thu Oct 15, 4:17PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $104.57 to a high of $112.67. Yesterday, the shares gained 6.2%, which took the trading range above the 3-day high of $108.99 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 117.53 (+0.50)
After Yesterday's Rally of 6.24% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Oct 15, 4:16PM CDT
Incyte (NASDAQ:INCY) traded in a range yesterday that spanned from a low of $104.57 to a high of $112.67. Yesterday, the shares gained 6.2%, which took the trading range above the 3-day high of $108.99 on volume of 2.2 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
INCY: 117.53 (+0.50)
Lilly-Incyte drug beats Humira
at Investor's Business Daily - Wed Oct 14, 5:35PM CDT
Rheumatoid arthritis drug baricitinib, created by Eli Lilly (LLY) and its partner Incyte (INCY), outperformed AbbVie's (ABBV) market-leading Humira in a clinical trial, the partners said. The study's primary endpoint was just to do better than a...
INCY: 117.53 (+0.50), ABBV: 59.55 (+5.45), LLY: 81.57 (-0.43)
Incyte & Merck Expand Melanoma Treatment Collaboration
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 2:50PM CDT
Incyte (INCY) and Merck (MRK) have expanded their collaboration agreement by including a phase III study on epacadostat in combination with Keytruda.
MRK: 54.66 (-0.21), INCY: 117.53 (+0.50), ANIK: 38.52 (-0.55), NVET: 4.35 (unch)
Eli Lilly, Incyte's Baricitinib Scores in Phase III Study
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 2:30PM CDT
Eli Lilly (LLY) and Incyte's baricitinib tops phase III rheumatoid arthritis study; strikes a T-cell-based immuno-oncology research collaboration ImaginAb Inc.
MRK: 54.66 (-0.21), INCY: 117.53 (+0.50), JUNO: 51.76 (+0.37), LLY: 81.57 (-0.43)
Lilly-Incyte Drug Beats Humira In Arthritis Trial
at Investor's Business Daily - Wed Oct 14, 10:12AM CDT
Big pharma Eli Lilly (LLY) and its biotech partner Incyte (INCY) said Wednesday that their rheumatoid-arthritis drug outperformed AbbVie's (ABBV) market-leading Humira in a clinical trial, sending both stocks higher. The study's primary endpoint for...
PFE: 33.82 (-0.95), INCY: 117.53 (+0.50), ABBV: 59.55 (+5.45), LLY: 81.57 (-0.43)
Why Incyte Corporation (INCY) Isn't Done Growing Earnings Yet
Zacks Equity Research - Zacks Investment Research - Wed Oct 14, 7:48AM CDT
Incyte Corporation (INCY) has double digit earnings growth prospect as it sees rising earnings estimates, coupled with a solid Zacks Rank.
INCY: 117.53 (+0.50)
Baricitinib Demonstrates Superiority to Adalimumab in Improving Signs and Symptoms of Rheumatoid Arthritis in Pivotal Phase 3 Study
PR Newswire - Wed Oct 14, 5:45AM CDT
Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) today announced positive topline results of RA-BEAM, the fourth successful Phase 3 study of baricitinib, an investigational medicine for patients with moderately-to-severely active rheumatoid arthritis.
INCY: 117.53 (+0.50), LLY: 81.57 (-0.43)
Incyte to Report Third Quarter Financial Results
Business Wire - Tue Oct 13, 7:00AM CDT
Incyte Corporation (Nasdaq: INCY) announced today that it has scheduled its third quarter 2015 financial results conference call and webcast for 10:00 a.m. ET on Tuesday, November 3, 2015.
INCY: 117.53 (+0.50)
Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda(R) (pembrolizumab) as First-line Treatment for Advanced Melanoma
Business Wire - Tue Oct 13, 6:30AM CDT
Incyte Corporation (Nasdaq: INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the expansion of the companies' ongoing clinical collaboration to include a Phase 3 study evaluating the combination of epacadostat, Incyte's investigational selective IDO1 inhibitor, with Keytruda(R) (pembrolizumab), Merck's anti-PD-1 therapy, as first-line treatment for patients with advanced or metastatic melanoma. The Phase 3 study, which is expected to begin in the first half of 2016, will be co-funded by Incyte and Merck.
MRK: 54.66 (-0.21), INCY: 117.53 (+0.50)
Why Incyte Corporation (INCY) Could Shock the Market Soon
Zacks Equity Research - Zacks Investment Research - Fri Oct 09, 7:40AM CDT
Incyte has seen a negative price movement but large positive earnings estimate revisions make it an unappreciated stock that might have potential for gains
INCY: 117.53 (+0.50)
3 Reasons Why Incyte Corporation (INCY) is a Great Momentum Stock
Zacks Equity Research - Zacks Investment Research - Wed Oct 07, 7:30AM CDT
Incyte Corporation (INCY) is an impressive stock as it has a strong Momentum Score, favorable Zacks Rank and is also seeing positive estimate revisions.
INCY: 117.53 (+0.50)
3 Large-Cap Biotech Stocks Whose Valuations Should Make You Skeptical
Sean Williams, The Motley Fool - Motley Fool - Wed Oct 07, 7:03AM CDT
Source: Federal Reserve Bank of New York. With the exception of the last couple of weeks, the biotech sector has been a vast outperformer since the Great Recession. The broad-based S&P 500 has pretty much tripled since hitting its lows in...
BIIB: 290.51 (-3.21), VRTX: 124.74 (-1.43), XBI: 66.63 (-0.68), INCY: 117.53 (+0.50)
Global Indolent Lymphoma Pipeline Review, H2 2015 - 17 Companies & 25 Drug Profiles
M2 - Wed Oct 07, 3:17AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q2nmbb/indolent_lymphoma) has announced the addition of the "Indolent Lymphoma - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Indolent Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Indolent Lymphoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Altor BioScience Corporation - Astellas Pharma Inc. - Bayer AG - Biothera, Inc. - Boehringer Ingelheim GmbH - Celgene Corporation - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Juno Therapeutics Inc. - Kite Pharma, Inc. - MedImmune, LLC - Merck & Co., Inc. - Merck KGaA - MorphoSys AG Drug Profiles - acalisib - ALT-803 - bendamustine hydrochloride - BI-836826 - CC-122 - copanlisib hydrochloride - DI-B4 - duvelisib - entospletinib - ibrutinib - idelalisib - Imprime PGG - INCB-39110 - INCB-40093 - INCB-50465 - JCAR-015 - KTE-C19 - lenalidomide - MEDI-0680 - MEDI-551 - MEDI-551 MEDI-0680 - MOR-208 - obinutuzumab - venetoclax - vorinostat For more information visit http://www.researchandmarkets.com/research/q2...t_lymphoma
KITE: 68.05 (-0.72), GILD: 108.13 (-1.08), MRK: 54.66 (-0.21), INCY: 117.53 (+0.50), JUNO: 51.76 (+0.37), INFI: 10.35 (+0.08), ABBV: 59.55 (+5.45), CELGZ: 1.65 (+0.17)
